Tag Archives: healthNews

Exclusive: Bloomberg charitable organization scrutinized by India for anti-tobacco funding, lobbying – documents

NEW DELHI (Reuters) – India continues to be investigating how Bloomberg Philanthropies, founded by millionaire Michael Bloomberg, funds local non-profit groups for anti-tobacco lobbying, government documents show, which makes it the most recent foreign non-government organization in the future under scrutiny.

Pm Narendra Modi’s government has since 2014 tightened surveillance of non-profit groups, saying these were acting against India’s national interests. A large number of foreign-funded charities’ licenses happen to be canceled for misreporting donations.

Critics, however, repeat the government has utilized the foreign funding law like a tool to silence non-profit groups that have elevated concerns concerning the social costs of India’s rapid economic development.

The intelligence wing of India’s home ministry this past year drafted an email on Bloomberg Philanthropies, raising concerns the foundation was managing a campaign to “target” Indian tobacco companies and “strongly” lobby from the sector.

Although the three-page note, reviewed by Reuters, stated the Bloomberg initiative’s “claimed intention to free India of tobacco can’t be faulted” because of the known risks from tobacco, it highlighted the sector’s importance, noting it earns nearly $5 billion in annual revenue for governments, and offers a livelihood for huge numbers of people.

“Foreign interests making foreign contributions … for purpose of lobbying against a recognised business activities raises multiple concerns,” the note stated, including, it stated, an “adverse economic impact” on 35 million people.

The June 3, 2016 note, marked “SECRET” and circulated to top government officials, including in Modi’s office, hasn’t formerly been reported. The probe ongoing until a minimum of April this season, another government document demonstrated.

Rebecca Carriero, a spokeswoman for Michael Bloomberg and New You are able to-based Bloomberg Philanthropies, declined to comment because they were not aware associated with a analysis.

A house ministry spokesman stated “queries which connect with security agencies can’t be clarified.” Modi’s office didn’t react to an e-mail seeking comment.

The ministry’s note was among the reasons for the rejection of the foreign funding license renewal with a minimum of one Bloomberg-funded India charitable organization last October, stated a senior government official conscious of the analysis.

Michael Bloomberg, among the world’s wealthiest people along with a former New You are able to City Mayor, has committed nearly $1 billion to aid global tobacco control efforts. Certainly one of his focus countries is India, where tobacco kills 900,000 people annually.

Apart from funding Indian NGOs, Bloomberg’s charitable organization has previously labored on improving road safety and supported federal tobacco-control efforts. In 2015, Modi known as Michael Bloomberg a “friend”, and also the two decided on cooperating on India’s ambitious intend to build so-known as smart metropolitan areas.


The house ministry note stated the Bloomberg charitable organization effectively lobbied for the development of bigger health warnings on cigarette packs, “contrary” towards the recommendations of the parliamentary panel.

FILE PHOTO: A lady smokes a beedi or local cigarette hands-folded with tobacco leaf on the roadside in New Delhi, India May 24, 2017.Adnan Abidi/File photo

As the panel known as is bigger of warnings to become greater than bending to 50 % of the pack’s area, the ministry searched for a greater figure of 85 %. Despite protests from India’s $10 billion cigarette industry, the final Court this past year purchased manufacturers to follow along with the greater stringent health ministry rules.

That, the note stated, was the very first from the three-phase Bloomberg campaign targeting India’s tobacco industry. It didn’t let you know that precisely the Bloomberg charitable organization lobbied.

As the note mirrored a number of India’s tobacco lobby’s positions – for example how anti-smoking policies could adversely impact maqui berry farmers – the federal government official stated the analysis wasn’t done in the behest of the profession.

“Anti-tobacco lobby really wants to kill revenue generating activities,” the state stated.

Any adverse health ministry official, however, stated: “We do not see tobacco being an business activities.Inch He added the health ministry was not aware of the house ministry’s note on Bloomberg Philanthropies.

FILE PHOTO: People light up along a road in Mumbai, India, October 26, 2016.Danish Siddiqui/File photo


India has walked up scrutiny of NGOs registered underneath the Foreign Contribution Regulation Act (FCRA).

In 2015, the house ministry place the Ford Foundation on the watch list and suspended Greenpeace India’s FCRA license, drawing critique in the U . s . States.

Captured, the federal government banned foreign funding for that Public Health First step toward India, an organization supported by the balance &amp Melinda Gates Foundation, saying it used foreign donations to “lobby” for tobacco-control policy issues, “that is prohibited under FCRA.”

Within the Bloomberg situation, the house ministry note incorporated a chart showing how funds ran from Bloomberg Philanthropies to the partner, the Campaign for Tobacco-Free Kids, that was then funding five local FCRA-registered NGOs. These NGOs, the note stated, appeared to be utilized by the Bloomberg charitable organization for “anti-tobacco lobbying activities.”

The FCRA license with a minimum of one of these – the Institute of Public Health (IPH) Bengaluru – wasn’t restored in October, partly because of the home ministry’s note, the federal government official stated.

The IPH stated it had been relayed through the house ministry that it is license wasn’t being restored based on a “field agency report”, but no details received. It had been not aware from the analysis on Bloomberg Philanthropies.

In April, the house ministry authored towards the federal health ministry, citing an “inquiry into foreign funding” for lobbying to alter laws and regulations in India. The letter, seen by Reuters, pointed out the Bloomberg initiative and directed the ministry to set of anti-tobacco lobbying by foreign contributors far away where tobacco is broadly used.

The ministry hasn’t yet sent that relate, another government official stated. The ministry didn’t respond to your questions.

For any graphic on Bloomberg’s efforts to lessen tobacco use globally click tmsnrt.rs/2iD1QcX

Reporting by Aditya Kalra in NEW DELHI, with a lot more reporting by Duff Wilson in NEW You are able to Editing by Sanjeev Miglani and Ian Geoghegan

Our Standards:The Thomson Reuters Trust Concepts.

AstraZeneca taps AI for drug discovery in cope with Berg

LONDON (Reuters) – AstraZeneca (AZN.L) has forged an investigation collaboration with Boston-based Berg, a professional in artificial intelligence for drug hunting, within the latest manifestation of big pharma’s curiosity about using supercomputers for drug discovery.

The tie-up will concentrate on finding and evaluating novel methods for treating Parkinson’s disease along with other nerve disorders.

Financial terms weren’t disclosed however the deal involves AstraZeneca supplying Berg with chemical fragments the U.S. company will look for potential drug candidates.

Berg’s scientists have previously used AI to locate novel biological targets for brand new medicines by evaluating detailed data from tissue samples collected from diseased and healthy individuals.

AstraZeneca may have the authority to secure a unique license to the drug candidates appearing out of the job.

An increasing number of big pharmaceutical companies, including GlaxoSmithKline (GSK.L), Sanofi (SASY.PA) and Merck (MRK.N) are exploring the potential for AI through alliances with start-ups.

The goal would be to harness modern computing systems to calculate how molecules will behave and just how likely they’re to create a helpful drug, therefore saving money and time on unnecessary tests.

“2017 has truly been the entire year when AI continues to be given serious attention and we’re now seeing early indications of adoption and implementation within the broader industry,” Niven Narain, leader of independently owned Berg, told Reuters. “In prior years there is some scepticism.”

For Berg, that also features its own experimental cancer drugs developed using AI in numerous studies, the offer with AstraZeneca is its initial pharma collaboration.

Narain expects to announce more partnerships soon. “There exists a couple of which are not far from being finalised,” he stated.

Other youthful companies within the AI drug discovery sector include Britain’s BenevolentAI and Exscientia, and U.S. based firms Numerate, twoXAR, Atomwise and InSilico Medicine.

Reporting by Ben Hirschler Editing by Elaine Hardcastle

Our Standards:The Thomson Reuters Trust Concepts.

Texas floodwaters pose unique health problems, U.S. experts say

CHICAGO (Reuters) – Catastrophic flooding from Hurricane Harvey increases the chance of affilictions varying from skin rashes to microbial and infections and bug-borne disease, U.S. public medical officials cautioned on Monday.

The best health risks comes from drowning, specifically for people held in vehicles, stated Renee Funk, affiliate director for emergency control over the Cdc and Prevention.

Deadly carbon monoxide poisoning from portable generators is yet another threat. “Regrettably, we predict you will see individuals who die from might individuals will be poisoned from this,Inch Funk stated inside a telephone interview.

But merely wading in floodwaters might cause skin rashes because a lot of water is contaminated with toxic chemicals that will get beaten up of people’s garages and power sheds.

“No. 1 factor we are worried about inside a ton is chemicals,” stated Funk, who advises individuals to shower and wash their hands soon after connection with floodwaters.

Bug-borne disease is a smaller amount of an instantaneous threat since the floodwaters will wash out most bug breeding sites for disease-causing nasty flying bugs such Aedes aegypti, which spread Zika, chikungunya, dengue and yellow fever, she stated.

Floods typically cause a boost in nuisance nasty flying bugs, like the Culex variety, which, too, can transport disease.

Annually after Hurricane Katrina in 2005, regions in Louisiana and Mississippi impacted by the ton reported a doubling of installments of neuroinvasive West Earth virus – cases where the virus caused severe inflammation within the brain or spinal-cord, stated Dr. Peter Hotez, dean from the National School of Tropical Medicine at Baylor College of drugs.

“Annually from now, we’ll need to look very carefully at West Earth along with other bug-borne infections,” stated Hotez, who’s riding the storm from his Houston home while his lab at Baylor is closed.

Within the immediate aftermath of Harvey, microbial illnesses really are a concern, although cholera, a scourge within the wake of numerous disasters in developing countries, is probably not really a worry in Houston, he stated.

“Microbial infections are actually important, for example salmonella and E. coli infections,” Hotez stated.

Shelters may also pose an open health risks, stated Dr. Amesh Adalja, a senior affiliate in the Johns Hopkins Center for Health Security.

“If you’re in a small enclosed area within an alternate care facility and you’ve got terrible diarrhea, it will likely be hard during these situations to rehearse proper infection control.”

Reporting by Julie Steenhuysen Editing by Howard Goller

Our Standards:The Thomson Reuters Trust Concepts.

Food and drug administration steps up scrutiny of stem cell therapies

(Reuters) – The U.S. Fda (Food and drug administration) is walking up efforts to higher regulate a growing field of drugs that holds significant promise to cure probably the most troubling illnesses using the body’s own cells.

A small amount of “unscrupulous actors” have grabbed around the commitment of regenerative medicine and stem cell therapies to mislead patients according to misguided, and perhaps, dangerously dubious products, the Food and drug administration stated on Monday. (bit.ly/2iB4Xls)

Regenerative medicine utilizes human cells or tissues which are engineered or obtained from contributors. Health regulators have approved some kinds of stem cell transplants – that mainly use bloodstream and skin stem cells – after numerous studies found they might treat certain kinds of cancer and also be skin grafts for burn victims.

However, many potential therapies continue to be within the earliest stages of development. These therapies are occasionally marketed using the commitment of a remedy, however they frequently have scant evidence backing their effectiveness or safety.

The Food and drug administration stated it’d taken steps to tackle the issue of some “troubling products” being marketed in Florida and California.

Federal officials on Friday grabbed from North Park-based StemImmune Corporation vials that contains countless doses of the vaccine reserved just for people at high-risk for smallpox, the Food and drug administration stated. (bit.ly/2wC1DMU)

The seizure adopted recent Food and drug administration inspections that confirmed the vaccine was utilized to produce an unapproved stem cell product, that was then provided to cancer patients, the company added.

The Food and drug administration also sent an alert letter to some Sunrise, Florida-based clinic for marketing stem cell products without regulatory approval as well as for major deviations from current good manufacturing practices. (bit.ly/2giGlx9)

The regulator will show a brand new policy framework this fall which will more clearly detail the “rules from the road” for regenerative medicine, Food and drug administration Commissioner Scott Gottlieb, a cancer survivor, stated inside a statement.

Reporting by Natalie Grover in Bengaluru Additional reporting by Tamara Mathias Editing by Sai Sachin Ravikumar

Our Standards:The Thomson Reuters Trust Concepts.

Gilead to purchase Kite Pharma for around $12 billion

(Reuters) – Gilead Sciences Corporation has decided to buy immunotherapy developer Kite Pharma Corporation within an all-cash deal worth $11.9 billion, the businesses stated on Monday.

Gilead pays $180 per share, representing a 29.4 % premium over Kite’s Friday close.

Gilead’s growth continues to be fueled by its pricey but revolutionary hepatitis C drugs however with less qualified patients and rising competition, sales have started to fall.

Wall Street and Gilead shareholders have lengthy been expecting the organization to make use of its cash pile for any big-ticket acquisition to reinvigorate its sales growth.

The offer, that has been authorized by the boards of both companies, is anticipated to shut within the 4th quarter of 2017.

Kite is among the leading players within an emerging field known as Vehicle-T, or chimeric antigen receptor T-cell therapy, which harnesses your body’s own immune cells to acknowledge and attack malignant cells.

If authorized by the Food and drug administration, Vehicle-T therapies might cost as much as $500,000 and generate vast amounts of dollars for his or her developers, analysts expect.

Kite Pharma’s experimental drug axi-cel is under expedited U.S. review for advanced non-Hodgkin lymphoma, with a lot more trials under means by leukemia patients.

The Wall Street Journal first reported the offer on Monday.

Kite’s shares were stopped in premarket buying and selling on Monday, while Gilead’s shares were up 2.7 %.

Reporting by Natalie Grover in Bengaluru Editing by Arun Koyyur

Our Standards:The Thomson Reuters Trust Concepts.

Novartis looking forward to novel heart drug, despite &#039modest&#039 benefit

ZURICH (Reuters) – Novartis will seek regulatory approval this season for any new type of anti-inflammatory heart drug, though some experts fear fatal infection risks along with a high cost may overshadow the medicine’s limited benefits.

Acutely anticipated medical trial results released on Sunday demonstrated heart-attack survivors on 1 of 3 doses of canakinumab were 15 % less inclined to suffer another major stroke than individuals on the placebo.

Novartis had stated in June the drug met its goal within the study but details were only unveiled at European Society of Cardiology meeting in Barcelona. One leading expert described the advantage as “modest”.

Patients getting canakinumab also endured considerably more deaths from infections than individuals on placebo – but, around the positive side, they made an appearance to become at lower chance of cancer.

There wasn’t any factor within the rate of deaths all causes between your placebo group and individuals on canakinumab.

“The modest absolute clinical advantage of canakinumab cannot justify its routine use within patients with previous myocardial infarction until we know much more about the effectiveness and safety trade-offs and unless of course a cost restructuring and formal cost-effectiveness evaluation supports it,” authored Dr. Robert Harrington, chair from the Stanford College Med school, within an editorial within the Colonial Journal of drugs.

Canakinumab had stirred considerable scientific interest since it seems to finally deliver proof that fighting inflammation provides a promising new method to counter cardiovascular disease in patients who already get cholesterol-lowering treatment.

Subsequently, some analysts boosted their revenue estimates for that Novartis medicine in to the vast amounts of dollars, while waiting for the information announced on Sunday.

Canakinumab has already been approved as Ilaris for rare autoimmune conditions.

Vas Narasimhan, Novartis’s mind of worldwide drug development, stated the drugmaker plans to visit regulators within the 4th quarter to find approval for canakinumab to deal with heart-attack victims rich in amounts of inflammation.

He downplayed critics who stated the advantage was small, stating that one large subgroup within the so-known as Cantos trial had proven a 27 percent decrease in cardiovascular risk.

Novartis also intends to underscore canakinumab’s potential cancer fighting qualities using the European Medicines Agency and also the U.S. Fda.


That’s after an analysis of Cantos data found total cancer mortality among patients getting canakinumab was considerably less than in individuals finding the placebo.

Narasimhan, who stated the organization now intends to start separate cancer trials for canakinumab, stated the drug might be particularly appropriate for smokers with perils of both cancer of the lung and heart disease.

Using the oncology findings promising only preliminary, the organization is planning additional studies in cancer of the lung beginning the coming year, he stated.

Ilaris now costs about $200,000 per patient yearly for the treatment of rare immune conditions and earns some $400 million in yearly sales for that Swiss company, though its cost will probably be slashed should it win approval within the heart setting.

Novartis initially battled using the sluggish launch of their last heart drug, the $4,500-per-year Entresto, so it’s understandably worried about the reception for canakinumab.

While Narasimhan stated it had been too soon to go over prices, he contended so-known as PCSK9 cholesterol drugs that cost about $14,000 yearly shouldn’t be trusted like a yardstick.

“Cellular the extra oncology findings, we do not think you need to just consider this like a cardiovascular drug,” Narasimhan stated. “I do not think you are able to always simply make comparisons to existing benchmarks, like the PCSK9s.”

Nevertheless, Tim Anderson, a Bernstein analyst, stated the “marginal” data aren’t compelling enough to eliminate what for Novartis will stay a prices conundrum, should canakinumab’s approval be expanded for heart patients.

“If the organization cuts the cost from the product in the current orphan indications, it instantly sacrifices sales which presently total about $400 million each year with the expectation that future sales inside a new CV setting will greater than offset this,” Anderson stated inside a note.

“Some have wondered whether an especially high-risk subgroup might be identified where canakinumab’s current cost could be justified,” he stated. “We’re not hopeful here.”

Reporting by John Miller Editing by Ben Hirschler and Rob Boulton

Our Standards:The Thomson Reuters Trust Concepts.

Bayer, J&J in frame for bigger anti-clotting market chance

FRANKFURT (Reuters) – Bayer and Manley &amp Johnson’s blockbuster clot prevention drug Xarelto was proven to chop the chance of potentially deadly strokes and cardiac arrest in patients with severe coronary artery disease by 24 percent, raising the prospects of billions more in sales.

Xarelto has already been approved for several cardiovascular conditions and protection against strokes brought on by atrial fibrillation, a kind of irregular heartbeat common one of the seniors, may be the primary profit driver.

The drug may potentially be utilized on $ 30 million additional patients in the largest national markets, once regulators give their go-ahead for that coronary artery disease indication, Bayer stated. That will come on the top of the population of roughly 25 million patients in atrial fibrillation.

Within the irregular heartbeat market, Xarelto is mind to mind with rival pill Eliquis, of Pfizer and Bristol-Myers Squibb, as well as competes with Boehringer Ingelheim’s Pradaxa, but not one of them happen to be tested within the coronary artery disease setting, due to the fact of concerns over negative effects.

The outcomes strengthen Bayer’s drugs division, which some investors say might be drained of funding among the planned $66 billion takeover of U.S. seeds maker Monsanto. However the trial success still leaves Bayer uncovered to some major slump in sales when Xarelto’s U.S. patent expires in 2024.

To date there’s no strong contender in the drug pipeline to part of after two setbacks in earlier stages of development in the last couple of years.

Detailed results presented in the European Society of Cardiology Congress in Barcelona over the past weekend demonstrated that a mix of Xarelto and aspirin was 24 percent more efficient at stopping strokes, cardiac arrest and cardiovascular deaths compared to standard management of aspirin alone.

The chances of suffering a stroke alone was slashed by 42 percent.


Investors were built with a peek at Xarelto’s bigger potential when independent supervisors from the trial in Feb stated the drug’s effectiveness am apparent that control patients within the trial who have been on aspirin only ought to be given Xarelto twelve months in front of schedule.

Around the lower-side, major internal bleeding that needed treatment happened 70 % more frequently in comparison to the aspirin-only group, though Bayer stated the chance of that occuring to some patient was still being low.

Bayer added the difference was mainly because of more gastrointestinal bleeding which there have been no signs that patients around the Xarelto-aspirin combination were uncovered to some bigger chance of potentially deadly bleeding within the brain or any other vital organs.

“As a whole, the advantages over-shadow along side it effect risks undoubtedly. You can observe it in the clearly decreased mortality rate which number also takes the instances of fatal bleeding into consideration,Inch stated Frank Misselwitz, mind of cardiovascular drug development at Bayer.

The chance of dying from the cause throughout the four-year trial was 18 percent reduced the Xarelto-plus-aspirin arm.

Participants endured from coronary heart (CAD) or peripheral artery disease (PAD), that are common types of progressively constricting arterial blood vessels within the legs, neck and round the heart. They’re typically given less expensive aspirin to avoid cardiovascular knock-on illnesses.

Bayer, which invented aspirin, elevated its annual peak sales potential estimate for Xarelto this past year to greater than 5 billion euros ($5.3 billion) as well as on Sunday stated it might keep that unchanged for the time being.

The pill generated 2.9 billion euros in 2016 sales for Bayer, up 30 % from last year, while partner J&ampJ, which will get most U.S. revenues, booked sales of $2.3 billion, up 23 percent.

Reporting by Ludwig Hamburger Editing by Andrew Bolton

Our Standards:The Thomson Reuters Trust Concepts.

Use of female condoms improving under State medicaid programs, but obstacles to make use of remain

(Reuters Health) – More states are earning female condoms available through State medicaid programs, new research found. But couple of women are utilizing them, researchers say.

The feminine condom is really a barrier contraceptive way in which protects against both undesirable pregnancy and also the transmission of sexually transmitted infections, or STIs. Female condoms happen to be available because the mid-1990s.

The amount of states where State medicaid programs, the federal government medical health insurance program for low-earnings individuals, provides women with female condoms rose greater than 30 % from 2007 to 2016, researchers report.

When Susan Witte in the Columbia College School of Social Operate in New You are able to City and colleagues contacted State medicaid programs representatives from each condition, they discovered that 36 states presently provide reimbursement for female condoms – 11 states greater than in 2007.

Twenty-nine states provided data on claims for female condoms between 2004 and 2014. Some states reported increases in reimbursements while some had decreases.

“Some states had a large number of claims, whereas others had couple of to none. Some states reimbursed thousands and thousands of dollars, but others reimbursed under $10 each year,Inches the authors authored within the American Journal of Public Health.

Overall, the figures of claims made an appearance to become low, based on the authors.

“Used properly, the feminine condom can offer just as much protection because the male condom,” Witte noted.

In addition, a lady can pick by herself for doing things and she or he can insert it herself, which is one of the couple of contraceptive options which are also drug and chemical-free, stated Witte.

But structural barriers, including poor marketing and too little accurate information, may hinder use of and utilisation of the device, Witte stated.

For ladies who be forced to pay on their behalf up front, retail cost is probably another barrier. Within the U.S., on Amazon . com.com, female condoms cost about $10 each. While a minumum of one study discovered that female condoms could be carefully washed and reused several occasions, the planet Health Organization recommends using a replacement for each act of sexual intercourse where there’s a danger of unplanned pregnancy or sexually transmitted infection, including Aids.

Witte believes growing awareness and building ‘peer norms’ is important to growing interest in female condom use.

“In short, basically utilize it, and that i speak with my pal about this, after which she informs her friend, starting to construct awareness to guide to elevated use,” she stated.

If demand would increase, supplies might increase, stated Witte.

Meanwhile, if medical professionals, including doctors, nurses, medical social workers, community health workers yet others understand about the tool and introduce it, more women would use it, she stated.

The U.S. Cdc and Prevention has more details about female condoms here: bit.ly/2wvtAWD.

SOURCE: bit.ly/2wJ6vPM American Journal of Public Health, online August 17, 2017.

Our Standards:The Thomson Reuters Trust Concepts.

Dementia dramatically increases family expenses

(Reuters Health) – The typical lifetime price of care following a proper diagnosis of dementia within the U.S. is all about $322,000, and families pay about 70% of this, new information suggests.

The price of care is $185,000 greater for somebody with dementia compared to someone without them, the research authors authored within the Journal from the American Geriatrics Society, online August 17.

“Dementia represents among the costliest illnesses, and the majority of the responsibility of dementia care falls on families,” stated lead study author Dr. Eric Jutkowitz of Brown College in Providence, Rhode Island.

Greater than 5 million Americans accept dementia, based on the Alzheimer’s Association. Time could rise to 16 million by 2050.

“For our lengthy-term care system to become sustainable, we have to provide families with effective sources and tools,” Jutkowitz stated by email.

Jutkowitz and colleagues used data in the Centers for Medicare and State medicaid programs Services and also the National Alzheimer’s Coordinating Center to estimate lifetime costs of care following a dementia diagnosis.

Overall, lifetime costs found $321,780. State medicaid programs, the federal government insurance for that poor, covered about 14%. Medicare, the government insurance program for that seniors and disabled, covered about 16%.

The 70% of costs following a dementia diagnosis born by families found $225,000, typically.

“We expected that dementia would cost lots of money which families would get in a large area of the cost,” Jutkowitz stated. “However, that which was surprising was the magnitude from the total costs and also the amount families incur.”

The study team estimates that the price of care could be $185,000 less for individuals without dementia.

“It’s worth noting that all this doesn’t start to touch the indirect costs for families, for example missed work and missed school, or even the lack of ability to consider that promotion or job in another city,” stated Dr. Amy Kelley from the Icahn Med school at Mount Sinai in New You are able to. Kelley, who wasn’t associated with this research, researches dementia healthcare costs.

“It’s striking to determine the task that people are facing,” she told Reuters Health by telephone. “What shall we be losing with regards to the workforce and also the perpetuation of poverty in families? It’s an even bigger issue.”

“Families have to be conscious that dementia can happen, also it could affect their parents, aunts, uncles, siblings, siblings and perhaps for them,Inches Dr. Michael Hurd from the RAND Corporation in Santa Monica, California told Reuters Health by telephone. “We have to consider the entire issue of how to deal with costs and care.”

Policymakers and medical service providers have to consider creating enough care facilities to assist dementia patients, he stated, in addition to technological advances that will help people age in your own home if facilities aren’t available.

“More individuals are facing the possibilities of dementia than previously,Inches Hurd stated. “We need to understand might time and financial effects.”

SOURCE: bit.ly/2wuTc5M

J Am Geriatr Soc 2017.

Our Standards:The Thomson Reuters Trust Concepts.

Surgeons in France reattach lady&#039s arms after train accident

PARIS (Reuters) – Surgeons have re-attached a ladies arms once they were severed with a train, an uncommon operation along with a first in France for the reason that both braches were labored on simultaneously.

The 4-hour procedure was conducted with a double team in the Center Hospitalier Universitaire Grenoble Alpes hospital in southeast France.

Surgery required started early at night of August. 14, 1 hour and 50 minutes following the 30-year-old’s arms were severed within the accident at Chambery station, 60 km (35 miles) away.

“How quickly the emergency services acted and also the skills from the medical team permitted both of your arms to become re-attached and provides the individual the perfect possibility of recovery because an excessive amount of delay may cause irreversible damage,” a healthcare facility stated inside a statement on its website.

Reporting by Andrew Callus editing by Andrew Roche

Our Standards:The Thomson Reuters Trust Concepts.